hi cafa and others, I have noticed eric van cutsem seems to have...

hi cafa and others, I have noticed eric van cutsem seems to have quite a good relationship with the company (providing positive feedback on SIRFLOX and actually coming to sydney last year to talk to institutional investors/analysts), I think this bodes well for SIRT's chances in being included in european treatment practice guidelines (which are followed more closely in europe than say, for example, US oncologists following the NCCN guidelines)

eric van cutsem actually authored the last ESMO treatment guidelines (2014) for mCRC, accessible here:
http://www.esmo.org/Guidelines/Gastrointestinal-Cancers/Metastatic-Colorectal-Cancer

note this was the first time SIRT was included, and this was before the sirlfox data was available

I think he will provide some exciting commentary at the upcoming conference, should be interesting!